P. Mitchell

发表

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

R. Herrmann, P. Marlton, J. Seymour, 2008, Leukemia & lymphoma.

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

S. Larson, A. Scott, J. Ingle, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non‐small cell lung cancer

S. Clarke, A. Broad, M. Links, 2011, Asia-Pacific journal of clinical oncology.

Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.

P. Beale, M. Friedlander, S. Clarke, 2006, Clinical colorectal cancer.

Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

S. Clarke, P. Beale, M. Friedlander, 2005, British Journal of Cancer.

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

S. Loi, B. Mukesh, J. Zalcberg, 2005, British Journal of Cancer.

Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer

A. Scott, H. Tochon-Danguy, David M. Thomas, 1998, The Medical journal of Australia.

Positron emission tomography scanning in the assessment of patients with lymphoma

S. Berlangieri, A. Scott, P. Mitchell, 2004, Internal medicine journal.

RESEARCH ARTICLE Prognostic Value of 18 F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma

A. Scott, S. Knight, S. Lee, 2009 .

Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.

A. Scott, M. Brechbiel, A. Hekman, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.

I. Davis, J. Cebon, M. Green, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

V. Apostolopoulos, G. Pietersz, B. Loveland, 2006, Clinical Cancer Research.

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.

T. John, M. Shackleton, B. Markman, 2020, Clinical lung cancer.

Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.

M. Links, A. McLachlan, Xuemin Jiang, 2008, British journal of clinical pharmacology.

A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer 1

S. Larson, A. Scott, J. Ingle, 2003 .

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

J. Zalcberg, I. Davis, J. Cebon, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield

S. Lade, J. Seymour, C. Stern, 2006, British Journal of Cancer.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

John R Zalcberg, Michael Michael, Mick Thompson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck.

S. Clarke, J. Zalcberg, D. Rischin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

D. Fielding, A. Musk, M. Byrne, 2002, British Journal of Cancer.

Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase.

R. Vaiskunaite, H. Do, R. Molania, 2017, Clinical chemistry.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

M. Quinn, G. Pietersz, B. Loveland, 2014, Journal of Immunotherapy for Cancer.

Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting

S. Fox, B. Solomon, H. Do, 2008, BMC Research Notes.

Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies

A. Scott, C. Baum, G. O'Keefe, 2012, EJNMMI Research.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

S. Clarke, D. Goldstein, B. Iacopetta, 2009, British Journal of Cancer.

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

S. Fox, H. Do, A. Dobrovic, 2008, BMC Cancer.

Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review.

T. Mok, P. Mitchell, M. van Kooten, 2012, Clinical lung cancer.

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma

B. Solomon, H. Do, A. Dobrovic, 2014, Scientific Reports.

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.

M. Friedlander, S. Clarke, D. Goldstein, 2006, Clinical colorectal cancer.

Prevalence of occult metastatic disease in patients undergoing 18F‐FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules

S. Berlangieri, G. O'Keefe, S. Knight, 2007, Internal medicine journal.

A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors

Matthew Links, Hui K. Gan, Paul de Souza, 2006, Cancer Chemotherapy and Pharmacology.

Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma

M. Feigen, A. Scott, S. Knight, 2009, Molecular Imaging and Biology.

Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung

H. Do, A. Dobrovic, C. Murone, 2010, Cell cycle.

The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL).

S. Bates, A. Scott, J. Zalcberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.